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Abstract
Background: Two families of polyunsaturated fatty acid (PUFA), omega-3 (ω-3) and omega-6 (ω-6), are required for
physiological functions. The long chain ω-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
have significant biological effects. In particular, DHA is a major component of cell membranes in the brain. It is also
involved in neurotransmission. Spinal cord injury (SCI) is a highly devastating pathology that can lead to catastrophic
dysfunction, with a significant reduction in the quality of life. Previous studies have shown that EPA and DHA can exert
neuroprotective effects in SCI in mice and rats. The aim of this study was to analyze the mechanism of action of ω-3
PUFAs, such as DHA, in a mouse model of SCI, with a focus on the early pathophysiological processes.
Methods: In this study, SCI was induced in mice by the application of an aneurysm clip onto the dura mater via
a four-level T5 to T8 laminectomy. Thirty minutes after compression, animals received a tail vein injection of
DHA at a dose of 250 nmol/kg. All animals were killed at 24 h after SCI, to evaluate various parameters implicated in
the spread of the injury.
Results: Our results in this in-vivo study clearly demonstrate that DHA treatment reduces key factors associated with
spinal cord trauma. Treatment with DHA significantly reduced: (1) the degree of spinal cord inflammation and tissue
injury, (2) pro-inflammatory cytokine expression (TNF-α), (3) nitrotyrosine formation, (4) glial fibrillary acidic protein
(GFAP) expression, and (5) apoptosis (Fas-L, Bax, and Bcl-2 expression). Moreover, DHA significantly improved the
recovery of limb function.
Furthermore, in this study we evaluated the effect of oxidative stress on dorsal root ganglion (DRG) cells using a
well-characterized in-vitro model. Treatment with DHA ameliorated the effects of oxidative stress on neurite
length and branching.
Conclusions: Our results, in vivo and in vitro, clearly demonstrate that DHA treatment reduces the development
of inflammation and tissue injury associated with spinal cord trauma.
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Background
Spinal cord injury (SCI) is defined as an acute traumatic
lesion of neural elements in the spinal canal (spinal cord
and cauda equina), resulting in a change, either tempor-
ary or permanent, in normal motor, sensory, or auto-
nomic function.
It is estimated that each year approximately 130,000
individuals worldwide sustain an acute SCI, joining a re-
cently estimated 2,500,000 who are already living with
chronic paralysis [1,2]. Spinal cord injury triggers the ac-
tivation of the innate as well as the adaptive immune
system. Innate immune cells present in the central ner-
vous system (CNS, microglia or astrocytes) or derived
from the blood (monocytes, macrophages and poly-
morphonuclear leukocytes, such as neutrophils) respond
very quickly to the injury [3,4], but their response is
nonspecific, since the molecules produced (reactive oxy-
gen species, such as superoxide) cause collateral damage
to surrounding tissue. Whether activation of the im-
mune system is detrimental or beneficial after SCI is a
question that is not easy to answer [5]. The beneficial or
detrimental effect of neuroinflammation probably de-
pends on the inflammatory mediators released during
particular phases of the inflammation that follows SCI
[6]. Spinal cord injury usually begins with a sudden,
traumatic blow to the spine that causes local segmental
damage to the spinal cord, which is called primary injury
[7,8]. The primary damage to tissue is followed by a sec-
ond phase of tissue degeneration, the secondary injury
that can occur over weeks or even months [8]. In second-
ary injury, acute inflammation can develop into a chronic
process if feedback mechanisms fail to inhibit amplifica-
tion of the inflammatory response. Chronic inflammation
leads to a continuous influx of neutrophils, macrophages,
lymphocytes, and eosinophils from the circulation, causing
more destruction and scarring of tissue. Cell death result-
ing from all of these mechanisms occurs through necrotic
and apoptotic phenomena or autophagia. In addition to
the spinal cord, spinal nerves and their associated dorsal
root ganglion (DRG) cells can be subject to mechanical
deformation and hypoxia associated with pathology, such
as spinal stenosis and spinal trauma. However, there is
very limited information on the response of adult DRG
neurons to such stressors, despite their obvious import-
ance to the function of the spinal cord.
There are no effective treatments for SCI, making this
condition one of the most challenging research topics.
Major progress has been made in preclinical studies on
neuroprotection and regeneration [2,9], but this progress
has not yet been translated to the clinic. Over the past 10
years, there has been increased interest in the health bene-
fits of polyunsaturated fatty acids (PUFAs), with evidence
emerging that ω-3 PUFAs have significant therapeutic po-
tential in a variety of CNS disorders, including Zellweger
syndrome, schizophrenia, depression, and Alzheimer’s dis-
ease [10,11]. PUFAs are structural components of phos-
pholipids, which are the main constituents of cell
membranes. The PUFAs of the ω-3 series include α-
linolenic acid, eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), the latter two being the longer
chain compounds, whereas α-linolenic acid is the biosyn-
thetic precursor. Recent evidence shows that ω-3 PUFAs
can modulate several of the processes that contribute to
secondary degeneration in the CNS [12]. There is evi-
dence that ω-3 PUFAs have antioxidant effects as well as
anti-inflammatory effects through inhibition of the pro-
duction of pro-inflammatory cytokines. PUFAs can also
block apoptosis, and several studies have documented
their neuroprotective effects in vitro and in vivo. Recently,
several studies have demonstrated that ω-3 PUFAs could
have significant therapeutic potential in the treatment of
SCI [13-17]. In these studies, the fatty acids were adminis-
tered within the first hour after injury and the outcome
was characterized using behavioral tests and tissue ana-
lysis several weeks after injury. Thus, there is still limited
information on the modulation by DHA of the very early
events after injury.
The purpose of this study is to investigate the effects
of ω-3 PUFAs treatment in a mouse compression model
of SCI and, in particular, to explore whether DHA could
reduce the early inflammatory response induced after
SCI. This experimental model of SCI express some of
the features of the injury response that are seen in hu-
man beings and are routinely used in research to assess
pain pathways, biochemical markers, morphology, and
path physiology. To improve SCI management, it is of
vital importance to explore novel therapeutics and gain
understanding of the pathophysiological processes
that follow traumatic injury to the spinal cord. In
addition, in this study we aim to provide information
on the response of adult DRG neurons to oxidative
stress, determining whether DHA is neuroprotective
in a well-characterized in-vitro model of injury, using




Male adult CD1 mice (25 to 30 g, Harlan Nossan, Milan,
Italy) were housed in a controlled environment and pro-
vided with standard rodent chow and water. Mice were
housed in stainless steel cages in a room kept at 22 ± 1°C
with a 12-h light, 12-h dark cycle. The animals were accli-
matized to their environment for 1 week and had ad-
libitum access to tap water and rodent standard diet.
The study was approved by the University of Messina
Review Board for the care of animals. All animal ex-
periments complied with regulations in Italy (DM
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116192) as well as EU regulations (OJ of EC L 358/1
12/18/1986).
SCI
Mice were anaesthetized using chloral hydrate (400 mg/kg
body weight). A longitudinal incision was made on the
midline of the back, exposing the paravertebral mus-
cles. These muscles were dissected away exposing the
T5 to T8 vertebrae. The spinal cord was exposed via
laminectomy and SCI was produced by extradural
compression of the spinal cord using an aneurysm clip
(using the aneurysm clip applicator oriented in the bi-
lateral direction) with a closing force of 24 g, at the T6
to T7 level, as described by Rivlin and Tator [18]. In all
injured groups, the spinal cord was compressed for 1
min. Sham-operated animals were only subjected to
laminectomy. Following surgery, 1.0 ml of normal sa-
line was administered subcutaneously, to replace the
blood volume lost during the surgery. During their re-
covery from anesthesia, the mice were placed on a
warm heating pad and covered with a warm towel.
During the period following injury, the animals’ blad-
ders were manually voided twice a day until the mice
were able to regain normal bladder function. Spinal
cord tissues were collected at 24 hours following
trauma.
Experimental groups Mice were randomly allocated into
the following groups:
1) SCI + vehicle group. Mice were subjected to SCI
plus administration of saline (via tail vein injection),
30 min after SCI (N = 40);
2) DHA group. As for the SCI + vehicle group, except
that DHA (250 nmol/kg, as used in a previous study
[12], was injected intravenously (tail vein injection),
30 min after SCI (N = 40).
3) Sham + vehicle group. Mice were subjected to the
same surgical procedures as the above groups except
that the aneurysm clip was not applied and saline
was injected intravenously 30 min after SCI (N = 40);
4) SCI PPARα KO + vehicle group. Mice were
subjected to SCI plus administration of saline (via
tail vein injection), 30 min after SCI (N = 40);
5) SCI PPARα KO + DHA group. As for the SCI +
vehicle group except that DHA (250 nmol/kg, as
used in a previous study [12] was injected
intravenously (tail vein injection), 30 min after SCI
(N = 40);
6) Sham PPARαKO + vehicle group. Mice were
subjected to the same surgical procedures as the
above groups except that the aneurysm clip was not
applied and saline was injected intravenously 30 min
after SCI (N = 40);
Mice (N = 10 from each group for each parameter)
were sacrificed at 24 h after SCI to evaluate the various
parameters.
In a separate set of experiments, another ten animals
for each group, both wild-type (WT) mice and PPARα
KO mice, were observed until 10 days after SCI, to
evaluate the motor score. The animals of the DHA
group received treatment with DHA (250 nmol/kg, as
tail vein injection) 30 min after SCI and daily until day
9; the motor score was assessed daily.
Preparation of the solution of docosahexaenoic acid
(DHA)
The fatty acid solution for intravenous administration
was prepared as follows: 1 M stock solution of DHA
(Sigma, UK) was prepared in ethanol under nitrogen
and then stored at −20°C. For the experiment, 5 μl ali-
quots of DHA (1 M in ethanol) were taken and diluted
in sterile NaCl 0.9% and the pH adjusted to 7.4. The
DHA solution (250 nmol/kg body weight), was adminis-
tered 30 minutes after injury in a tail vein, under light
anesthesia using sevoflurane.
Grading of motor disturbance
The motor function of mice subjected to compression
trauma was assessed once a day for 10 days after injury.
Recovery from motor impairment was graded using the
Basso mouse scale (BMS) open-field score [19], since the
BMS has been shown to be a valid locomotor rating
scale for mice. The evaluations were made by two blind
observers for all analyzed groups. The BMS scale ranges
from 0 (indicating complete paralysis) to 9 (indicating
normal hind limb function), and rates locomotion on
such aspects of hind limb function as weight support,
stepping ability, coordination, and toe clearance. The
BMS score was determined for ten mice in each group.
Immunohistochemical localization of TNF-α, nitrotyrosine,
iNOS, Fas-L, GFAP, Bax, and Bcl-2
Spinal cord tissues were taken at 24 h following trauma,
and were fixed for 24 h in paraformaldehyde solution (4%
in PBS 0.1 M) at room temperature, dehydrated by graded
ethanol, and embedded in Paraplast (Sherwood Medical,
Mahwah, NJ). Sections 8 μm thick were cut from the
paraffin-embedded tissue. After deparaffinization, en-
dogenous peroxidase was quenched with 0.3% (v/v)
hydrogen peroxide in 60% (v/v) methanol for 30 minutes.
The sections were permeabilized with 0.1% (w/v) Triton
X-100 in PBS for 20 minutes. Nonspecific adsorption was
minimized by incubating the section in 2% (v/v) normal
goat serum in PBS for 20 minutes. Endogenous biotin or
avidin binding sites were blocked by sequential incubation
for 15 minutes with biotin and avidin (Vector Laborator-
ies, Burlingame, CA, USA), respectively. Sections were
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incubated overnight with anti-nitrotyrosine rabbit poly-
clonal antibody (SantaCruz Biotechnology 1:500 in PBS,
v/v), anti-iNOS rabbit polyclonal antibody (BD Transduc-
tion 1:500 in PBS, v/v), anti-Bax rabbit polyclonal antibody
(SantaCruz Biotechnology 1:500 in PBS, v/v), or anti-Bcl-2
rabbit polyclonal antibody (SantaCruz Biotechnology
1:500 in PBS, v/v), anti-Fas ligand (Fas-L) rabbit poly-
clonal antibody (SantaCruz Biotechnology 1:500 in PBS,
v/v), anti-tumor necrosis factor (TNF)-α rabbit polyclonal
antibody (SantaCruz Biotechnology 1:500 in PBS, v/v),
and with anti-glial fibrillary acidic protein (anti-GFAP)
mouse monoclonal antibody (1:500; Cell Signaling Tech-
nology). Sections were washed with PBS and incubated
with peroxidase-conjugated bovine anti-mouse immuno-
globulin G (IgG) secondary antibody or peroxidase-
conjugated goat anti-rabbit IgG (1:2,000 Jackson Immuno
Research, West Grove, PA, USA). Specific labeling was de-
tected with a biotin-conjugated goat anti-rabbit IgG or
biotin-conjugated goat anti-mouse IgG and avidin-biotin
peroxidase complex (Vector Laboratories, Burlingame,
CA, USA). To verify the binding specificity for nitrotyro-
sine, iNOS, Bax, and Bcl-2, Fas-L, TNF-α, and anti-GFAP,
control sections were also incubated with only the primary
antibody (no secondary) or with only the secondary anti-
body (no primary). In these controls, no positive staining
was found in the sections, indicating that the immunore-
action was positive in all the experiments. Immunohisto-
chemical photographs were assessed by densitometric
analysis using an imaging densitometer (AxioVision, Zeiss,
Milan, Italy). Briefly, for each tissue section at least ten op-
tical fields in the area at the boundary between the nec-
rotic core and the penumbra area (perilesioned area) and
ten optical fields distal to the damaged area were counted,
as described previously [20]. Replicates for each experi-
mental condition and histochemical staining were ob-
tained from each mouse in each experimental group. In
sham-operated mice, the central areas of corresponding
tissue sections were taken as reference points, and a com-
parable number of optical fields were counted. Data are
expressed as a percentage of total tissue area, as described
previously [21].
H & E staining
Paraffin tissue sections (thickness, 5 μm) were deparaf-
finized with xylene, stained with H & E, and studied
using light microscopy (Dialux 22, Leitz, Germany).
Segments of each spinal cord were evaluated by an ex-
perienced histopathologist. Damaged neurons were
counted and the histopathological changes of the gray
matter were scored on a 6-point scale [22]: 0 = no le-
sion observed; 1 = gray matter contained one to five
eosinophilic neurons; 2 = gray matter contained five to
ten eosinophilic neurons; 3 = gray matter contained
more than ten eosinophilic neurons; 4 = small infarction
(less than one-third of the gray matter area); 5 = moderate
infarction; (one-third to one-half of the gray matter area);
6 = large infarction (more than one-half of the gray matter
area). The scores from all the sections from each spinal
cord were averaged to give a final score for an individual
mouse. All the histological studies were performed in a
blinded fashion.
Preparation of cytosolic and nuclear extracts from spinal
cord and Western blot analysis
Cytosolic and nuclear extracts were prepared as de-
scribed previously [23], with slight modifications. Briefly,
2 cm tissue segments containing the lesion from each
mouse were suspended in extraction buffer A containing
0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.15 mM
pepstatin A, 20 mM leupeptin, 1 mM sodium orthovana-
date, homogenized at the highest setting for 2 minutes,
and centrifuged for 15 minutes at 4°C. Supernatants repre-
sented the cytosolic fraction. The pellets (containing
enriched nuclei) were resuspended in buffer B containing
1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl pH
7.4, 1 mM ethylene glycol tetraacetic acid, 1 mM ethylene-
diaminetetraacetic acid, 0.2 mM PMSF, 20 μm leupeptin,
0.2 mM sodium orthovanadate. After centrifugation for 30
minutes at 15,000 g at 4°C, the supernatants containing
the nuclear protein were stored at −80°C for further ana-
lysis. The levels of IκB-α, Bax, and Bcl-2 were quantified
in the cytosolic fraction from spinal cord tissue collected
after 24 h after SCI, whereas NF-κB p65 levels were quan-
tified in the nuclear fraction. Protein concentration was
determined with the Bio-Rad protein assay kit. Proteins
(40 μg) were dissolved in Laemmli Sample Buffer, boiled
for 5 minutes, and subjected to sodium dodecyl sulfate
PAGE (10% or 12% polyacrylamide). Proteins were sepa-
rated electrophoretically and transferred to nitrocellulose
membranes. Membranes were blocked with 5% (w/v) non-
fat dried milk in buffered saline (PM) for 45 minutes at
room temperature and subsequently probed with specific
antibodies: anti-IκB-α (1:1.000; Santa Cruz Biotechnol-
ogy), anti-Bax (1:500; Santa Cruz Biotechnology), anti-Bcl-
2 (1:500; SantaCruz Biotechnology), anti-Fas-L (1:500;
SantaCruz Biotechnology), anti-iNOS (1:1000; BD trans-
duction), or anti- NF-κB p65 (1:500 SantaCruz Biotech-
nology) in 1× PBS, 5% w/v nonfat dried milk, and 0.1%
Tween-20 (PMT) at 4°C overnight. Membranes were incu-
bated with peroxidase-conjugated bovine anti-mouse
immunoglobulin G (IgG) secondary antibody or peroxidase-
conjugated goat anti-rabbit IgG (1:2.000, Jackson Immuno Re-
search, West Grove, PA) for 1 h at room temperature.
To ascertain that Western blots were loaded with
equal amounts of protein lysates, they were also incu-
bated in the presence of the antibody against β-actin (for
cytosolic extract) or lamin A/C (for nuclear extract) pro-
teins (1:10.000; Sigma-Aldrich Co., Milan, Italy). Signals
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were detected with the enhanced chemiluminescence
detection system reagent, according to the manufac-
turer’s instructions (SuperSignal West Pico Chemilu-
minescent Substrate, Pierce, Thermo Fisher Scientific
Inc., Rockford, IL, USA).
Immunofluorescence
After deparaffinization and rehydration, detection of
GFAP, TNFα, Bax, and Iba-1 was carried out after boil-
ing in 0.1 M citrate buffer for 1 min. Nonspecific ad-
sorption was minimized by incubating the section in 2%
(v/v) normal goat serum in PBS for 20 min. Sections
were incubated with mouse monoclonal anti-GFAP
(1:100, v/v Santa Cruz Biotechnology), polyclonal rabbit
anti-TNFα (1:100, v/v Santa Cruz, Biotechnology), rabbit
anti-Bax (1:100, v/v Santa Cruz Biotechnology), or mouse
monoclonal anti-Iba-1 (1:100, v/v Santa Cruz Biotechnol-
ogy) antibody in a humidified chamber for O/N at 37°C.
Sections were washed with PBS and incubated with sec-
ondary antibody FITC-conjugated anti-mouse Alexa
Fluor-488 antibody (1:2000 v/v Molecular Probes, UK)
and with TEXAS RED-conjugated anti-rabbit Alexa Fluor-
594 antibody (1:1000 in PBS, v/v Molecular Probes, UK)
for 1 h at 37°C. Sections were washed; for nuclear staining
2 μg/ml 4′,6′-diamidino-2-phenylindole (Hoechst, Frank-
furt; Germany) in PBS was added. Cells were observed at
×20 magnification using a Leica DMRD microscope
(Leica). All images were digitalized at a resolution of 8 bits
into an array of 2048 × 2048 pixels. Optical sections of
fluorescence specimens were obtained using a HeNe laser
(543 nm), an UV laser (361 to 365 nm) and an Ar laser
(458 nm) at a 1-min, 2-s scanning speed with up to eight
averages; 1.5-μm sections were obtained using a pinhole
of 250 nm. Contrast and brightness were established by
examining the most brightly labeled pixels and applying
settings that allowed clear visualization of structural de-
tails while keeping the highest pixel intensities close to
200. The same settings were used for all images obtained
from the other samples that had been processed in paral-
lel. Digital images were cropped and figure montages pre-
pared using Adobe Photoshop 7.0 (Adobe Systems; Palo
Alto, CA).
Materials
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Company Ltd (Milan, Italy). All
stock solutions were prepared in nonpyrogenic saline
(0.9% NaCl; Baxter, Italy) or 10% dimethyl sulfoxide.
Statistical evaluation
All values in the figures and the text are expressed as
mean ± standard error of the mean (SEM). Results
shown in the figures are representative of at least three
experiments performed on different in-vivo experimental
days. In each experiment, we used five animals per group,
unless otherwise indicated. The results were analyzed by
one-way analysis of variance followed by a Bonferroni
post-hoc test for multiple comparisons. A P value of less
than 0.05 was considered significant.
In-vitro procedures
Primary DRG neuron culture
Primary neuronal cultures were prepared according to
the method of Gavazzi and colleagues [24], with some
modifications, as described here. Adult male CD1 mice
25 to 30 g (Charles Rivers, UK) were sacrificed by inhal-
ation of CO2, followed by decapitation. All procedures
were carried out in accordance with the UK Animals
(Scientific Procedures) Act 1986 and associated guide-
lines. Cervical to lumbar level DRGs were removed and
cleaned before being dissociated chemically with 0.125%
collagenase (Type 4; Worthington, UK) at 37°C for 45
minutes. The collagenase concentration was then raised
to 0.25% for another 45 minutes and the ganglia were
washed and dissociated with 0.25% trypsin (Sigma, UK)
for a further 15 minutes. The tissue was then triturated
with a pipette tip until homogeneously dissociated in
serum-free medium (BSF-2) consisting of 1% N-2 sup-
plement (Invitrogen, UK), 0.3% bovine serum albumin
(BSA) (Fraction V; Sigma, UK) and 100 unit/ml penicil-
lin and 100 μg/ml streptomycin (Sigma, UK) in Ham’s
F-12 medium (Invitrogen, UK). The cell suspension
was then centrifuged at 400 rpm (30 g) for 5 minutes
followed by resuspension and a second centrifugation
through a 15% BSA (Sigma, UK) cushion at 900 rpm
(153 g) for 10 minutes. Cellular debris collected at the
BSA/BSF-2 interface was removed along with the
remaining supernatant. The pelleted cells were resus-
pended in BSF-2 containing glial cell-line derived
neurotrophic factor (25 ng/ml, R&D Systems, UK).
The cell suspension was plated out onto either glass
coverslips double-coated with poly-D-lysine (5 μg/ml;
Sigma, UK) and laminin (10 μg/ml; Sigma, UK) and
left to adhere for 1 h before BSF-2 was added to cover
the surface of the wells. Cultures were maintained at
37°C in a humidified atmosphere with 5% CO2 / 95%
air for 48 h prior to further experiments.
Preparation of omega-3 PUFAs
Stock solutions of 1 M DHA (Sigma, UK) were diluted to
1 mM with BSF-2 under nitrogen and stored at −20°C.
These stock solutions were then diluted as required with
BSF-2 and adjusted to pH 7.4 using sodium hydroxide.
The chosen final concentration of DHA was 1 μM. Etha-
nol was added to the medium and used as the vehicle
control in the in-vitro experiments, as this was the
solvent initially used to dissolve the PUFA. The final
concentrations of ethanol in the vehicle-exposed
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cultures were identical to those present in the DHA
preparations.
Oxidative stress injury model
A single 12-well culture plate (Sigma, UK) was used for
each experiment. Existing BSF-2 was first removed from
all wells in culture plates and fresh BSF-2 was added.
Dorsal root ganglias were cultured for 48 h before 1 μM
DHA final concentration or vehicle was added, immedi-
ately before the induction of oxidative stress with hydro-
gen peroxide (Sigma, UK) 10 nM for 24 hours. For
dilution of stock solutions of both DHA and H2O2, BSF-
2 media was used.
Immunocytochemistry
After 24 h from the induction of the oxidative stress,
DRG cultures were fixed with ice-cold 4% paraformalde-
hyde for 5 minutes at room temperature. Cultures were
stained with anti-β-tubulin III primary antibody (1:1000
Sigma, UK). Cultures were then washed and incubated
with the appropriate anti-mouse secondary antibodies
with Alexa Fluor-488 (1:2000 Molecular Probes, UK).
Cultures were also counterstained with the fluorescent
nuclear stain, 4′,6′-diamidino-2-phenylindole (Hoechst
2 μg/ml; Sigma, UK). Cells were observed at ×20 magni-
fication using a Leica DMRD microscope (Leica, UK).
Images were captured using a Hamamatsu (Hamamatsu,
Japan) digital camera and HiPic32 imaging software.
Adobe Photoshop 7 was used to produce micrographs.
Neurite outgrowth assay
Neurite growth was assessed for the entire neuronal
population. Cultures were stained with β-tubulin III for
visualization of neurites. For each experimental condi-
tion, images of 50 neurons were recorded for each ani-
mal (n = 3) and imported into NeuronJ, an ImageJ
plugin (National Institute of Health, USA).
The length of the longest neurite, total neurite out-
growth, and number of branches was also measured; im-
ages of 50 neurons were recorded for each animal (n = 3)
and imported into the MetaMorph analysis program
(Molecular Devices, USA). The number of neurons
with neurites was also recorded.
Statistical analysis
For the in-vitro study, results are expressed as mean ±
SEM of three experiments, with each experiment using
ganglia pooled from two animals. A two-way analysis of
variance (ANOVA) was used to compare the overall ef-
fect of treatment and injury on cell death, followed by
post-hoc multiple pairwise comparisons using Tukey’s




DHA reduces the severity of SCI in the thoracic region of
spinal cord
The severity of trauma at the level of the perilesional
area, assessed by the presence of edema as well as as-
sessment of alterations of white matter, was evaluated by
H & E staining (Figure 1) at 24 h after trauma. Signifi-
cant damage to the spinal cord was observed in tissue
from mice subjected to SCI (Figure 1B, see histological
score Figure 1D) when compared with sham-operated
mice (Figure 1A, see histological score Figure 1D). Not-
ably, a significant protection against SCI was observed in
DHA-treated mice (Figure 1C,C1, see histological score
Figure 1D). To evaluate whether histological damage to
the spinal cord was associated with a loss of motor func-
tion, the BMS open-field score was used. Motor function
was not impaired in sham mice. Mice subjected to SCI
showed significant deficits in hind limb movement
(Figure 1E) starting with the first evaluation performed
24 h after trauma. In the DHA-treated mice group, the
neurological score improved in a statistically signifi-
cant way beginning at four days after chronic adminis-
tration, compared with the SCI-vehicle mice group,
and persisted up to 10 days after SCI.
Effect of DHA on IκB-a degradation and NF-κB p65 nuclear
localization
To analyze the molecular mechanisms by which DHA treat-
ment may attenuate the development of SCI, we evaluated
by Western blot analysis the classical NF-κB pathway, evalu-
ating both IκB-α levels and NF-κB nuclear localization. A
basal level of IκB-α was detected in the spinal cord sections
from sham-operated animals (Figure 2A), whereas SCI sub-
stantially reduced IκB-α levels (Figure 2A). DHA prevented
the SCI-induced IκB-α degradation and restored IκB-α to
levels similar to those in sham-operated mice (Figure 2A).
In addition, SCI caused a significant increase in the nuclear
NF-κB p65 levels compared with the sham-operated mice
(Figure 2B). DHA treatment significantly decreased NF-κB
p65 expression (Figure 2B).
Effect of DHA on IκB-a degradation and NF-κB p65 nuclear
localization
It has been known that after SCI, astrocytes become re-
active as a response to damage [25]. In this study, using
GFAP staining, we show that SCI induces a glial re-
sponse, which reflects that astrocytes become activated,
as indicated by staining for GFAP cells in injured animals
compared with sham animals (Figures 3B and A respect-
ively, see densitometric analysis, Figure 3G). Instead, the
treatment with DHA decreased the number of reactive as-
trocytes (GFAP-activated astrocytes) (Figure 3C, see densi-
tometric analysis Figure 3G).
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To test whether DHA modulates the inflammatory
process through the regulation of the secretion of pro-
inflammatory cytokines, we analyzed the spinal cord
levels of TNF-α, by immunohistochemical staining.
There was no staining for TNF-α in spinal cord ob-
tained from sham mice (Figure 3D, see densitometric
analysis H). A substantial increase in TNF-α expression
was found in inflammatory cells as well as in nuclei of
Schwann cells in the white and gray matter of the
spinal cord tissues collected from mice at 24 h after
SCI (Figure 3E, see densitometric analysis Figure 3H).
Spinal cord expression of TNF-α was significantly attenu-
ated in DHA-treated SCI mice in comparison with SCI
animals (Figure 3F, see densitometric analysis Figure 3H).
Figure 2 Effects of DHA treatment on IκBα and nuclear NF-κB p65. By Western blot analysis, a basal level of IκB-α was detected in the spinal
cord from sham-operated animals (A), whereas IκB-α levels were substantially reduced in SCI mice (A). DHA treatment reduced the SCI-induced
IκB-α degradation (A). In addition, SCI caused a significant increase in nuclear NF-κB p65 compared with sham-operated mice (B). DHA treatment
significantly reduced the phosphorylation of p65 on Ser536 and the translocation into the nucleus of NF-κB p65 (B). A representative blot of
lysates obtained from each group is shown, and densitometry analysis of all animals is reported. Respective densitometry analysis of protein
bands from three separated experiments is reported (***P < 0.001 vs. Sham; ###P < 0.005 vs. SCI; ## P<0.05 vs.SCI).
Figure 1 Effect of DHA treatment on histological alterations of the spinal cord tissue 24 h after injury and on hind limb motor
disturbance. No histological alterations have been found in the spinal cord tissue collected from sham-operated mice (A, see histological score
D). A significant damage to the spinal cord was assessed in SCI-operated mice stained with H & E (B see histological score D). The treatment with
DHA resulted in a significant decrease in the extent and severity of the histological signs (C, see histological score D). Moreover, the degree of
motor disturbance was assessed every day until 10 days after SCI by Basso mouse scale (BMS) open-field score. Treatment with DHA administered
30 min after trauma reduces the motor disturbance after SCI (E). This figure is representative of at least three experiments performed on different
experimental days. ND: not detectable. Values shown are mean ± SEM of ten mice for each group; *P < 0.01 vs sham; °P < 0.01 vs SCI.
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Moreover, to confirm astrogliosis and TNFα expression
and to localize it to specific cells types, we performed im-
munofluorescence staining. Spinal cord sections were
double stained with antibodies against GFAP (green), Iba1
(green) and TNFα (red). Spinal cord sections revealed in-
creased astrogliosis (GFAP + cells) in SCI mice (Figure 4E,
H) such as activation of the microglia (Figure 4R). GFAP
immunoreactivity and microglia activation were sig-
nificantly reduced in SCI-treated mice (Figure 4I,L).
The yellow spots indicate the colocalization between
TNFα and GFAP (Figure 4H,L) a as well as between
TNFα and Iba1 (Figure 4U,Y). Reported images are
representative of triplicate experiments. All images
were digitalized at a resolution of 8 bits into an array
of 2048 × 2048 pixels.
DHA modulates iNOS expression and nitrotyrosine
formation after SCI
To determine the levels of NO produced during SCI,
iNOS expression was evaluated by immunohistochemical
analysis and Western blotting in the spinal cord sections
24 h after SCI. Spinal cord sections from sham-operated
mice did not stain for iNOS (Figure 5A, see densitometric
analysis Figure 5G), whereas spinal cord sections obtained
from SCI-operated mice exhibited positive staining for
iNOS (Figure 5B, see densitometric analysis Figure 5G),
mainly localized in various inflammatory cells in the gray
matter. Treatment with DHA reduced the degree of posi-
tive staining for iNOS in the spinal cord tissues (Figure 5C,
see densitometric analysis Figure 5G). Moreover, by West-
ern blot analysis we observed an increased expression of
Figure 3 Effects of DHA on astrocyte activation and TNF-α expression in spinal cord tissue. Spinal cord sections were processed 24 h after
SCI to determine the immunohistological staining for GFAP and TNF-α expression. Sham animals never express GFAP (A, see densitometry analysis
G), the number of GFAP+ cells was significantly increased upon induction of SCI, due to astrocytes proliferation around the central canal (B, see
densitometry analysis G).Treatment with DHA significantly decreased the activation of astrocyte-GFAP+ cells (C, see densitometry analysis
G).Moreover, no positive staining for TNF-α was found in the spinal cord tissue from sham-operated mice (D, see densitometry analysis H). A substantial
increase in TNF-α expression was found in spinal cord tissues from SCI mice 24 h after SCI (E, see densitometry analysis H). DHA treatment
significantly attenuated TNF-α levels in the spinal cord (F, see densitometry analysis H). (G,H) Densitometry analysis of immunohistochemistry
photographs (n = 5 photos from each sample collected from all mice in each experimental group) for GFAP and TNF-α from spinal cord tissues. The
figure is representative of at least three experiments performed on different experimental days. For each SCI group see the high magnification of the
images. Data are expressed as percentage of total tissue area. Data are mean ± SEM of ten mice for each group.*P < 0.05 vs. Sham. °P < 0.01 vs. SCI.
ND: not detectable.
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iNOS levels in the group subject to SCI compared with
the control group (Figure 4H); while the treatment with
DHA reduced iNOS expression significantly (Figure 5H).
Moreover, 24 h after SCI, nitrotyrosine, a specific
marker of nitrosative stress, was measured by immunohis-
tochemical analysis in the spinal cord sections to deter-
mine the localization of “peroxynitrite formation” and/or
other nitrogen derivative produced during SCI. Spinal
cord sections from sham-operated mice did not stain for
nitrotyrosine, whereas spinal cord sections obtained from
SCI mice exhibited positive staining for nitrotyrosine
(Figure 5D and E respectively, see densitometric analysis
I). The positive staining was mainly localized in inflamma-
tory cells as well as in the nuclei of Schwann cells in the
white and gray matter of the spinal cord tissues. DHA re-
duced the degree of positive staining for nitrotyrosine in
the spinal cord (Figure 5F see densitometric analysis I,
data are means ± SEM of 10 mice for each group *p < 0.01
vs. sham, °p < 0.01 vs SCI and vehicle. ND: not detectable).
DHA modulates expression of Fas ligand after SCI
Immunohistochemical staining for Fas ligand in the
spinal cord was also determined at 24 h after injury.
Spinal cord sections from sham-operated mice did not
stain for Fas ligand, whereas those obtained from SCI
mice exhibited positive staining for Fas ligand (Figure 6A,
see densitometric analysis Figure 6D) mainly localized in
various cells in the gray matter. Treatment with DHA
reduced the degree of positive staining for Fas ligand in
the spinal cord (Figure 6C, see densitometric analysis
Figure 6D). Moreover, we Western blot analysis for Fas-
L revealed an increased expression in the group subject
to SCI (Figure 6E) compared with the control group,
while treatment with DHA reduced Fas-L expression
significantly (Figure 6E).
Effects of DHA on apoptosis in spinal cord after injury
To test whether spinal cord damage was associated with
cell death, we evaluated the appearance of the pro-
apoptotic protein Bax by Western blot analysis at 24 h
after SCI. Bax levels were appreciably increased in the
spinal cord tissue collected from mice subjected to SCI
(Figure 7G). In contrast, treatment with DHA prevented
SCI-induced Bax expression (Figure 7G). To detect Bcl-
2 expression, whole extracts from the spinal cord of each
mouse were also analyzed by Western blotting. Expression
Figure 4 Colocalization of GFAP/TNFα and Iba1/TNFα after SCI. Results are shown for (A-D, M-P) sham-operated mice, (E-H, R-U) mice with
SCI and (I-L, V-Y) mice with SCI treated with DHA. Spinal cord sections were double stained with antibodies against GFAP (A,E,I, green), Iba1 (M,
R,V, green) and TNFα (B,F,J,N,S,W, red). Spinal cord sections revealed increased astrogliosis (GFAP + cells) in SCI mice (E, R). GFAP immunoreactiv-
ity was reduced in DHA-treated mice (I, V). Yellow spots indicate co-localizations (H, U) and revealed a high colocalization between GFAP/TNFα
and Iba1/TNFα double staining.
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of the anti-apoptotic protein Bcl-2 was apparent in spinal
cord homogenates from sham-operated mice (Figure 7H).
Twenty-four hours after SCI, Bcl-2 expression was signifi-
cantly reduced in spinal cord samples from SCI mice
(Figure 7H). Treatment of mice with DHA significantly
blunted the SCI-induced inhibition of Bcl-2 expression
(Figure 7H).
To confirm our data on apoptotic proteins, we also de-
termined Bax and Bcl-2 expression by immunohistochem-
ical staining. Immunohistochemical staining for Bax and
Bcl-2 also showed that spinal cord sections from sham-
operated mice did not stain for Bax (Figure 7A), whereas
SCI-operated mice exhibited positive staining for Bax
(Figure 7B). DHA treatment reduced the degree of
positive staining for Bax in spinal cord samples from
mice subjected to SCI (Figure 7C).
In addition, spinal cord sections from sham-operated
mice demonstrated Bcl-2 positive staining (Figure 7D),
whereas in SCI mice, the staining was significantly re-
duced (Figure 7E). Treatment with DHA attenuated the
loss of positive staining for Bcl-2 in the spinal cord from
SCI-subjected mice (Figure 7F).
Moreover, to confirm Bax expression and to localize it
to specific cell types, we performed immunofluorescence
staining. Spinal cord sections were double stained with
antibodies against GFAP (green), Iba1 (green) and Bax
(red). Spinal cord sections revealed increased expression
of Bax in SCI mice (Figure 8F,S). Bax activation was
Figure 5 Effects of DHA on nitrotyrosine formation and iNOS expression. Immunohistochemical and Western blot analysis in the spinal cord
section 24 h after SCI. Sections from sham-operated mice did not stain for iNOS (A, see densitometry analysis G), whereas those from SCI-
operated mice exhibited staining for iNOS (B, see densitometry analysis G) mainly in various inflammatory cells in the gray matter. Treatment with
DHA reduced the degree of staining for iNOS (C, see densitometry analysis G). Moreover, by Western blot analysis we observed high levels of
iNOS in the SCI group (H), whereas the DHA treatment group revealed a low expression of iNOS (H). Thus, the tissue sections obtained from SCI
mice demonstrate staining for nitrotyrosine mainly localized in inflammatory cells and in Schwann cell nuclei in the white and gray matter (E, see
densitometry analysis I). DHA treatment reduced the degree of staining for nitrotyrosine (F, see densitometry analysis I). Conversely, spinal cord
from sham-operated mice did not stain for nitrotyrosine (D, see densitometry analysis I). For each SCI group, see the high magnification of the
images. (G,I) Densitometry analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for iNOS and nitrotyrosine. Data expressed as a percentage of total tissue area. This figure is representative of at least
three experiments performed on different experimental days. Data are mean ± SEM of ten mice for each group.*P < 0.01 vs sham; °P < 0.01
vs SCI; ND: not detectable.
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reduced in SCI-treated mice (Figure 8J,W). The yellow
spots indicate the colocalization between Bax and
GFAP (Figure 8H,L) as well as between Bax and Iba1
(Figure 8U,Y). Reported images are representative of
triplicate experiments. All images were digitalized at a
resolution of 8 bits into an array of 2048 × 2048 pixels.
Role of functional PPAR-α gene in the protective and
anti-inflammatory properties of DHA of the degree of
spinal cord trauma
As PPAR-α is constitutively expressed in astrocytes and
neurons, it has been proposed that PPAR-α regulates
brain and spinal cord lipid homeostasis during physio-
logical conditions. PPAR-α activation may improve fatty
acid mobilization, supporting both functional modifica-
tion and structural reorganization in the dorsal horn of
the spinal cord, such as activation of the arachidonate
cascade, or axon sprouting. To better study the mechan-
ism of action of DHA, we inflicted SCI on PPARα KO
mice. Spinal cords from uninjured mice appeared nor-
mal by gross and microscopic examination (Figure 9A,
see histological score Figure 9D). Twenty-four hours
after the trauma, intraparenchymal hemorrhages and cell
swelling were visible throughout the white matter of in-
jured cords (Figure 9B, see histological score Figure 9D)
compared with sham-operated mice. PPAR-α deletion
increased spinal cord edema, which is a well-recognized
cause of secondary neuronal damage after SCI in human
beings and animals. The genetic absence of the PPAR-α
in KO mice significantly reduced the effect of the DHA
treatment (Figure 9C, see histological score Figure 9D).
Traumatic SCI results in severe inflammation and
decreased cellular regeneration, which lead to difficult
functional recovery. Open-field locomotor function
was tested using the BMS, from 1 day post injury
through to the end of the study (10 days). While motor
function was only slightly impaired in sham-operated
mice, a significant increase in hind limb motor distur-
bances was observed in the PPAR-αKO operated mice
(Figure 9E). The genetic absence of the PPAR-α recep-
tor significantly blocked the effect of the DHA treat-
ment (Figure 9E).
Figure 6 DHA treatment reduced Fas-ligand expression in the perilesional spinal cord tissue. No positive staining for Fas ligand was
found in the spinal cord tissue collected from sham-operated mice (A, see densitometry analysis D). A substantial increase in Fas-ligand expression
was found in inflammatory cells, and in white and gray matter of spinal cord tissues collected at 24 h after SCI (B, see densitometry analysis D). Spinal
cord levels of Fas ligand were significantly attenuated by DHA treatment (C, see densitometry analysis D). (D) Densitometry analysis of
immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental group) for Fas ligand.
Moreover Western blot analysis revealed an increased expression of Fas-L in the SCI group (E), whereas DHA treatment significantly reduced
the increased levels of Fas-L (E). Figure is representative of at least three experiments performed on different experimental days. Data are
mean ± SEM of ten mice for each group. *P < 0.01 vs Sham; °P < 0.01 vs SCI. # P<0.01 vs SCI; ND: not detectable.
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In-vitro study
Effect of DHA on neurite growth
In the DRG culture, approximately 15% of the total cells
are neuronal (β-tubulin III positive) and 20% are Schwann
cells. The remainder of the non-neuronal cells are mainly
satellite cells, with some fibroblasts. Each DRG subpopu-
lation was determined as a percentage of the total neuron
population, identified by counterstaining with the pan-
neuronal marker β-tubulin III (mouse).
To assess the morphology of the cells in more de-
tail, DRG cells were stained with β-tubulin III for
visualization of the neurites. As shown in Figure 10,
the oxidative stress induced by the administration of
H2O2 significantly decreased the outgrowth of the
DRG neurons in culture (Figure 10C,D) compared
with the control DRG cells group (Figure 10A,B),
whereas treatment with DHA (1 μM) increased the
percentage of cells with complex growth, similar to
the control DRG cells (Figure 10E,F).
Effect of DHA on neurite length and number of branches
The number of neurons with neurites (as total out-
growth), the neurite process length, and the number of
branches were all seen to be reduced in H2O2 injured
cultures (Figure 11A,B,C, respectively), compared with
control DRG cells group (Figure 11A,B,C, respectively).
Injury may result in neurons halting their neurite
growth, or may lead to a selective loss of cells that have
long neurites. Total outgrowth, length of longest neurite
and number of branches were all markedly increased in
Figure 7 Effects of DHA on intrinsic apoptotic pathway. Staining for Bax expression was absent in the sham group (A). Twenty-four hours
after SCI, spinal cord tissue from injured animals showed positive staining for Bax (B). DHA treatments significantly reduced the SCI-induced Bax
(C). On the contrary, positive staining for Bcl-2 was observed in the spinal cord tissues from sham-operated mice (D) while the staining was
significantly reduced in SCI mice (E). DHA treatment attenuated the loss of positive staining for Bcl-2 in the spinal cord from SCI- subjected
mice (F). For Bax staining in SCI groups, see the high magnification of the images; for Bcl2 staining, see high magnification for sham and
DHA groups. Moreover, an increase in Bax expression was evidenced by Western blot analysis (G). DHA treatment reduced the expression
for Bax in the spinal cord ganglia). A basal level of Bcl-2 expression was detected in spinal cord from sham-operated mice (H). Twenty-four
hours after SCI, Bcl-2 expression was significantly reduced in spinal cord from SCI mice (H). DHA treatments significantly reduced the SCI-induced
inhibition of Bcl-2 expression (H). A representative blot of lysates obtained from each group is shown, and densitometry analysis of all
animals is reported. Respective densitometry analysis of protein bands from three separated experiments is reported. Data are mean ± SEM
of ten mice for each group; ***P < 0.001 vs. sham; ###P < 0.005 vs. SCI. ND: not detectable.
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the DRG cells treated with DHA 1 μM (Figure 11A,B,C,
respectively).
Discussion
Spinal cord injury has a high prevalence and a profound
impact on both the patient and on society as a whole.
Functional recovery following SCI is often poor and, as
yet, there are no nonsurgical therapies that have been
translated to the clinic. The corticosteroid methylpred-
nisolone is the only recognized pharmacological treat-
ment that modulates the early inflammatory reaction
after SCI in human beings [26]. However, methylpred-
nisolone has not been included in the standard care of
SCI patients worldwide, since its use has been shown to
have adverse side effects, including metabolic complica-
tions and an increased risk of wound infection. Drug ad-
ministration that is safe and efficacious is vital for
optimal treatment. In the search for potential thera-
peutic targets, increasing attention has been focused on
the molecular events that occur immediately after SCI.
Direct mechanical damage to neurons, axons, glia cells
and blood vessels induces the release of molecules that
lead to glial activation and initiation of secondary in-
flammation. Various strategies to interfere with these
events have been tested experimentally and some have
been pursued in human clinical trials. However, the
question of how to treat patients at this time still re-
mains open. In this work, an in-vivo injury model of SCI
was used, to replicate some of the typical features of the
inflammatory conditions after SCI. Moreover, we tried to
elucidate whether the exogenous administration of DHA
can protect against SCI. Lang-Lazdunski et al. [22] had
initially shown, in a model of transient spinal cord ische-
mia in rats, that the administration of an omega-3 fatty
acid, α-linolenic acid, after injury, decreased neuronal
loss and improved functional outcome. Moreover, previ-
ous studies of Lim et al. [16] demonstrated that omega-
3 DHA, administered as an intravenous bolus after SCI
induced by hemisection of the spinal cord in adult rats,
induced significant neuroprotection, reducing neuronal
cell loss and oligodendrocyte loss, and decreasing the
apoptosis measured 1 or 6 weeks after injury. In addition,
it has been shown that DHA can counteract glutamate-
induced excitotoxicity. As inflammation, excitotoxicity
Figure 8 Colocalization of GFAP/Bax and Iba1/Bax after SCI. Results are shown for (A-D, M-P) sham-operated mice, (E-H, R-U) mice with SCI
and (I-L, V-Y) mice with SCI treated with DHA. Spinal cord sections were double stained with antibodies against GFAP (A,E,I, green), Iba1 (M,R,V,
green) and Bax (B,F,J,N,S,W, red). Spinal cord sections revealed increased Bax expression in SCI mice (F,S). Bax expression was reduced in
DHA-treated mice (J,W). Yellow spots indicate co-localizations (H,U) and revealed a high colocalization between GFAP/Bax and Iba1/Bax
double staining.
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and oxidative stress are part of the pathogenetic mech-
anism involved in the secondary injury associated with
SCI [20], this led us to explore the potential of DHA as
a neuroprotective agent, targeting the very early events
after SCI, within 24 h. Spinal cord injury results in a
necrotic area of cavitation that progressively increases
in area due to secondary neuronal death promoted by
acute inflammation, edema, apoptosis, and glial scar-
ring. The acute loss of motor neurons and degener-
ation of white matter tracts results most often in
irreversible motor dysfunction. In this work, we clearly
demonstrated that DHA treatment attenuates the de-
gree of secondary inflammation and improves motor
recovery. This is consistent with previous results ob-
tained in static compression SCI in rats [13,14] and
mice [16]. A variety of experimental evidence suggests
that activation of the transcription factor NF-κB plays
a central role in the regulation of many genes respon-
sible for the generation of mediators or proteins in-
volved in secondary inflammation associated with SCI
[27]. There is good evidence that ω-3 PUFAs inhibit
the activation of NF-κB, by preventing the phosphoryl-
ation of IK kinase, hence preventing the degradation of
IκB, and resulting in transactivation of NF-κB target
genes [28]. DHA antagonizes the NF-κB signaling
pathway, inhibiting the expression of inflammatory
genes downstream of NF-κB. We report here that SCI
is associated with significant IκB-α degradation as well
as increased nuclear expression of p65 in spinal cord
tissues 24 h after injury. Treatment with DHA signifi-
cantly reduced IκB-α degradation as well as NF-κB
localization. NF-κB plays a central role in the regula-
tion of many genes responsible for the generation of
mediators or proteins in inflammation. These include
the genes for TNF-α, IL-1β, iNOS, and COX-2 [29]. In
this regard, it has been well demonstrated that in SCI
the expression of pro-inflammatory cytokines, such as
TNF-α and IL-1β, regulates the precise cellular events
after SCI. We confirm in this study that SCI leads to a
substantial increase in the levels of TNF-α. Remark-
ably, there was no increase in the expression of TNF-α
in the spinal cord sections obtained from mice treated
with DHA. Therefore, the inhibition of the production
of TNF-α by DHA described in this study can most
probably be attributed to the inhibitory effect of the
activation of NF-κB. Moreover, previous studies have
shown that TNF-α activates iNOS and induces the
generation of NO-radical (NO) from L-arginine [30].
This study demonstrates that DHA attenuates the ex-
pression of iNOS in the tissue from SCI-treated mice
when compared with untreated injured mice. It has
also been demonstrated that peroxynitrite, a cytotoxic
molecule generated when nitric oxide (NO) and super-
oxide (O2−) combine, probably contributes to second-
ary neuronal damage through pathways resulting from
the chemical modification of cellular proteins and
lipids in the secondary neuronal damage of SCI [31].
Nitrotyrosine formation, along with its detection by
Figure 9 Involvement of peroxisome proliferator-activated receptors on the protective actions of DHA following spinal cord trauma.
Following spinal cord compression, significant damage to the spinal cord from PPARα KO mice (B) at the perilesional zone was observed by H &
E staining when compared with spinal cord tissue collected from the sham group (A). The genetic absence of the PPAR-α receptor significantly blocked
the effect of the DHA treatment (C). The histological score (D) was made by an independent observer. These figures are representative of at least three
experiments performed on different experimental days. Data are mean ± SEM of ten mice for each group. *P < 0.01 vs sham; °P < 0.01 vs SCI.
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immunostaining, was initially proposed as a relatively
specific marker for the detection of the endogenous
formation ‘footprint’ of peroxynitrite. Increased nitro-
tyrosine staining is considered, therefore, as a marker
of increased nitrosative stress rather than a specific
marker of the peroxynitrite generation. In this study,
we have found that the damage induced by SCI is asso-
ciated with an intense immunostaining for nitrotyro-
sine. We clearly demonstrated that treatment with
DHA significantly prevents the appearance of nitrotyr-
osine staining.
Another important mediator of secondary damage after
SCI is the apoptosis process [30]. We report in this study
that the treatment with DHA in our SCI experimental
model reduces apoptosis markers, suggesting that DHA
could be beneficial for treatment of SCI. In particular, we
demonstrate that the treatment with DHA reduced Bax
expression while, conversely, Bcl-2 is expressed much
more in mice treated with DHA. It can be hypothesized
that DHA is able to attenuate this apoptotic cell death,
which often occurs at a slower rate than necrosis, upregu-
lating the expression of the Bcl-2 family of anti-apoptotic
proteins, while downregulating the apoptotic proteases
caspase-3 and 9, and pro-apoptotic signaling proteins in-
cluding Bax, Bad, Bid, and Bik, in a number of cell types
including neurons and oligodendrocytes. This could ac-
count for some of the neuroprotection seen in the present
study.
In addition, a variety of evidence has shown that Fas
ligand plays a central role in apoptosis induced by a var-
iety of chemical and physical insults. Fas co-localizes in
many TUNEL-positive cells, suggesting that Fas-initiated
cell death cascades may participate in the demise of
some glia following SCI. We clearly demonstrated that
DHA significantly reduced the Fas-ligand expression in-
duced by SCI. Based on this evidence, we have shown
clearly that DHA interferes with the apoptotic process
induced by SCI. However, it is not possible to exclude
the possibility that the anti-apoptotic effects observed
after DHA treatment are secondary to an attenuation of
the inflammatory reaction.
Moreover, recent studies suggested that PUFAs, and in
particular omega-3 fatty acids, are endogenous ligand for
RXR and PPAR receptors. Thus, we hypothesized that a
Figure 10 Representative fluorescence microscopy images of DRG cultures stained with neuronal marker. DRG cells were stained with β-tubulin
III to visualize the neurites. Oxidative stress induced by the administration of H2O2 significantly decreased the outgrowth of the DRG neurons in culture
(C, D) compared with the control DRG cells group (A, B), whereas the treatment with DHA increased the percentage of cells with complex growth,
similar to the control DRG cells (E, F). Cells were counterstained with Hoechst.
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marked neuroprotective role of omega-3 PUFA is pos-
sibly driven by the activation of these receptors. So our
study investigated whether the protective and anti-
inflammatory effects of DHA observed in a compression
model of SCI are partially mediated by PPAR receptor
activation and in particular by PPAR-α isotypes. To
characterize the role of PPAR-α in DHA-mediated anti-
inflammatory and neuroprotective activities, we inflicted
spinal cord trauma on PPARα KO mice. The results of
this study indicated that PPAR-αKO mice are more sus-
ceptible to induction of SCI than are WT mice, possibly
owing to a less efficient anti-inflammatory control exerted
by endogenous PPAR-α ligand; moreover we demon-
strated in this study that the genetic absence of the PPAR-
α in KO mice significantly reduced the protective effect of
the DHA treatment that we observed in WT mice. Results
discussed here suggest a new mechanism of action for
DHA contributing to determining the full DHA efficacy
and suggest future studies should aim to analyze the pos-
sible relevance of the other PPAR isoforms, such as PPAR-
β/δ and PPAR-γ, in DHA-mediated protection in SCI.
In this study, we also tested the efficacy of ω-3 PUFA
in an in-vitro model of DRG cell culture [32]. In particu-
lar, we studied the role of DHA in an oxidative stress
model induced by administration of H2O2 in culture
medium in the presence or absence of DHA. Oxidative
stress is associated with many CNS and peripheral ner-
vous system (PNS) pathologies, including SCI, and pro-
tection of neuronal and non-neuronal cells against this
type of injury is of considerable importance. The ability
to protect neurons against cell death is crucial to suc-
cessful recovery after a traumatic neuronal injury, since
regeneration in the PNS can only occur from neurons
that survive the initial trauma. In the case of trauma to
the CNS, where spontaneous regeneration is severely
limited, protection of neurons becomes even more crit-
ical. In this study, the in-vitro model of DRG cell culture
demonstrated that the injury induced by H2O2 mediated
oxidative stress was significantly attenuated by supple-
mentation of the media with DHA (1 μM). Total out-
growth, length of longest neurite and number of branches
were all increased in the cultures that received the admin-
istration of DHA (1 μM) compared to cultures that were
subjected to the oxidative stress and had no treatment.
The increase in neurite extension is in agreement with the
work of others, which shows that a priming injury re-
sults in a rapidly elongating mode of growth of neu-
rons in vitro [32].
Figure 11 Effect of DHA on neurite outgrowth. Neurite process length and number of branches were significantly reduced in H2O2-injured
cultures (A,B,C), compared with control DRG cells (A,B,C). Total outgrowth, length of longest neurite and number of branches were all
markedly increased in the DRG cells treated with DHA (A,B,C). Data are mean ± SEM of ten mice for each group. ***P < 0.001 vs Ctr; ### P < 0.005
vs H2O2; ** P < 0.01 vs Ctr; # P < 0,05 vs H2O2.
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This is the first study to demonstrate that DHA is
neuroprotective in an in-vitro model of oxidative stress
in DRG neurons. The in-vitro model allowed for an in-
vestigation into the neuroprotective effects of ω-3
PUFAs in adult DRG cultures. DHA was found to be a
very potent neuroprotector, and this is one of the key
findings of the work. This study also confirmed that
DHA was neuroprotective when given as a post-injury
treatment. This suggests that DHA could be of benefit
when administered after a traumatic injury, which is an
important factor when considering translation to the
clinic.
Conclusions
In-vitro models are a useful tool for screening neuropro-
tective agents and for determining their mechanisms of
action. Nevertheless, testing in vivo is essential for the
development of a therapy and successful translation
from the bench to the bedside. The results obtained in
this work also provide an indication that DHA could in-
crease the rate of regeneration of neurons and axons
after trauma. To conclude, both in-vitro and in-vivo ex-
periments point to the neuroprotective and neurotrophic
effects of long chain ω-3 PUFAs, such as DHA, which
could also lead to a secondary effect on regeneration fol-
lowing a SCI. This potential avenue demonstrates that
further research into the mechanisms leading to the in-
creased rate of recovery after DHA is warranted.
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